Free Trial
NASDAQ:RARX

Ra Pharmaceuticals (RARX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$47.99
$47.99
50-Day Range
$47.99
$48.00
52-Week Range
$19.64
$48.02
Volume
30,200 shs
Average Volume
1.16 million shs
Market Capitalization
$2.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RARX stock logo

About Ra Pharmaceuticals Stock (NASDAQ:RARX)

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

RARX Stock News Headlines

RA: Discount Continues To Leave Some Opportunity
Central Bank Ditches U.S. Dollar
Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.
RARX_old Historical Data
Central Bank Ditches U.S. Dollar
Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.
See More Headlines
Receive RARX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2020
Today
7/17/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RARX
Fax
N/A
Employees
72
Year Founded
N/A

Profitability

Net Income
$-102,690,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3 million
Book Value
$5.56 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.27 billion
Optionable
Optionable
Beta
1.05
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Douglas A. Treco (Age 61)
    Co-Founder, Pres, CEO & Director
  • Mr. David C. Lubner (Age 55)
    Exec. VP & CFO
  • Dr. Ramin Farzaneh-Far (Age 42)
    Chief Medical Officer
  • Mr. Alonso Ricardo
    Chief Technology & Innovation Officer and Head of Research
  • Dr. Simon Read (Age 48)
    Chief Scientific Officer

RARX Stock Analysis - Frequently Asked Questions

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) announced its earnings results on Thursday, February, 27th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.16.

When did Ra Pharmaceuticals IPO?

Ra Pharmaceuticals (RARX) raised $75 million in an initial public offering on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

What other stocks do shareholders of Ra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Novavax (NVAX), Viking Therapeutics (VKTX), Verastem (VSTM), Zynerba Pharmaceuticals (ZYNE) and Amarin (AMRN).

This page (NASDAQ:RARX) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners